SLC5A2 and heart failure: In the study population, adding SGLT2 inhibitors for 2 years prevented 32 deaths and 228 hospitalizations for heart failure, and increased 49 life years for every 1,000 patients treated, and showed an enhanced cost-effectiveness over time.